| Verifiedfields: | changed |
| Verifiedrevid: | 477221136 |
| Iupac Name: | 4-(phenylmethyl)piperidine |
| Legal De: | The NpSG do not apply to this substance, because it is not a 2-Phenylethylamine derivative |
| Legal Uk: | PSA |
| Cas Number: | 31252-42-3 |
| Unii: | JDF1T4667S |
| Pubchem: | 31738 |
| Chemspiderid: | 29432 |
| Chembl: | 144129 |
| C: | 12 |
| H: | 17 |
| N: | 1 |
| Smiles: | C1CNCCC1CC2=CC=CC=C2 |
| Stdinchi: | 1S/C12H17N/c1-2-4-11(5-3-1)10-12-6-8-13-9-7-12/h1-5,12-13H,6-10H2 |
| Stdinchikey: | ABGXADJDTPFFSZ-UHFFFAOYSA-N |
4-Benzylpiperidine is a drug and research chemical used in scientific studies. It acts as a monoamine releasing agent with 20- to 48-fold selectivity for releasing dopamine versus serotonin. It is most efficacious as a releaser of norepinephrine, with an EC50 of 109 nM (DA), 41.4 nM (NE) and 5246 nM (5-HT).[1] It has a fast onset of action and a short duration. It also functions as a monoamine oxidase inhibitor (MAOI) with preference for MAO-A.[2]
4-Cyanopyridine can be reacted with toluene to give 4-benzylpyridine.[3] Catalytic hydrogenation of the pyridine ring then completes the synthesis.[4]
RMI-10608 is a derivative of 4-benzylpiperidine and analog of haloperidol that was discovered to have potential use in treating psychosis and preventing brain damage by virtue of its NMDA antagonist pharmacology.[5] [6]